Home Clinical Topics FDA approves new treatment for sickle cell disease

FDA approves new treatment for sickle cell disease

On July 7, the U.S. Food and Drug Administration (FDA) approved Endari (L-glutamine oral powder) for patients age 5 years and older with sickle cell disease to reduce severe complications associated with the disorder. Read more

Previous articleNew tool for detecting concussion
Next articleIn Brief

LEAVE A REPLY

Please enter your comment!
Please enter your name here